SAN DIEGO, CA (February 2, 2015) – PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, announced today that it broadened its SUBWAY® Restaurants* sales and marketing initiative as an invited preferred vendor presenter at the January 2015 SUBWAY® Winter Meeting of Multi Unit Owners in Miami, Florida.
The conference was attended by Multi Unit Owners (MUOs) and Development Agents (DAs) representing the nearly 27,000 SUBWAY® stores nationwide. The DAs are responsible for franchise store growth and managing franchise development.
The unparalleled benefits of using PURE® Hard Surface (PHS) disinfectant on critical food contact surfaces was showcased in the New Products/Technologies Forum. After meeting with MUOs and DAs to discuss and demonstrate the superior antimicrobial effectiveness of PHS, PURE received commitments to order and begin using the product from DAs representing multiple regions.
Cliff R. Wechsler, Executive Vice President Sales, said, “We launched our SUBWAY® sales initiative in Q4 2014 and several regions have placed initial orders. We are very pleased that we successfully built upon that phased rollout at this event, further accelerating our market rollout initiative. We are building momentum, having touched more than 5,000 stores at this conference. We came away with new orders, commitments for orders and appointments to hold rollout meetings in the next several weeks with key franchisees.
“We accomplished our goals -- garnering new orders from half a dozen new markets and generating solid new interest representing the potential to gain additional users. More than 20 new markets have requested additional samples and/or meetings with their local franchisees. PURE has educated an ever widening audience about eliminating potential food borne pathogens, and clearly demonstrated the benefits that SUBWAY® stores gain from using PHS.”
Wechsler concluded, “Feedback from attendees included an appreciation for the relatively low-cost to stores to incorporate an extra layer of protection against Norovirus, Listeria, and other pathogens. Store owners understood that our one step process is a simpler, more effective and environmentally friendly solution to help them protect their brand and deliver consistent results from store to store.”
* SUBWAY® is a registered trademark of Doctor's Associates Inc.
About PURE Bioscience, Inc.
PURE Bioscience, Inc. is focused on developing and commercializing our proprietary antimicrobial products primarily in the food safety arena -- providing solutions to the health and environmental challenges of pathogen and hygienic control. Our technology platform is based on patented stabilized ionic silver, and our initial products contain silver dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic antimicrobial agent, which offers 24-hour residual protection and formulates well with other compounds. As a platform technology, SDC is distinguished from existing products in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at www.purebio.com.
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause our actual results to differ materially from the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the Company’s cash position and liquidity requirements; the Company’s failure to implement or otherwise achieve the benefits of its proposed business initiatives and plans; acceptance of the Company's current and future products and services in the marketplace, including acceptance of the Company’s PURE Hard Surface disinfectant by SUBWAY® franchisees; the ability of the Company to develop effective new products and receive regulatory approvals of such products, including the required regulatory approvals to use its SDC-based technology as a direct food contact processing aid; competitive factors; dependence upon third-party vendors, including to manufacture its products; and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission, including our quarterly report on Form 10-Q filed on December 11, 2014. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.
Peter C. Wulff, CFO & COO
PURE Bioscience, Inc.